We have developed a monoclonal antibody (mAb) cocktail (ZRC-3308) comprising of ZRC3308-A7 and ZRC3308-B10 in the ratio 1:1 for COVID-19 treatment. The mAbs were designed to have reduced immune effector functions and increased circulation half-life. mAbs showed good binding affinities to non-competing epitopes on RBD of SARS-CoV-2 spike protein and were found neutralizing SARS-CoV-2 variants B.1, B.1.1.7, B.1.351, B.1.617.2 and B.1.617.2 AY.1 in vitro. The mAb cocktail demonstrated effective prophylactic and therapeutic activity against SARS-CoV-2 infection in Syrian hamsters. The antibody cocktail appears to be a promising candidate for the prophylactic use and for therapy in early COVID-19 cases which have not progressed to severe disease.

中文翻译：

---

ZRC3308 单克隆抗体鸡尾酒在叙利亚仓鼠中显示出对 SARS-CoV-2 感染的保护作用

我们开发了一种单克隆抗体 (mAb) 鸡尾酒 (ZRC-3308)，由 ZRC3308-A7 和 ZRC3308-B10 以 1:1 的比例组成，用于 COVID-19 治疗。mAb 旨在降低免疫效应功能并延长循环半衰期。mAb 对 SARS-CoV-2 刺突蛋白 RBD 上的非竞争表位显示出良好的结合亲和力，并被发现可以中和 SARS-CoV-2 变体 B.1、B.1.1.7、B.1.351、B.1.617.2 和B.1.617.2 AY.1体外。mAb 鸡尾酒对叙利亚仓鼠的 SARS-CoV-2 感染显示出有效的预防和治疗活性。抗体鸡尾酒似乎是预防性使用和治疗未进展为严重疾病的早期 COVID-19 病例的有希望的候选者。